Prospective Study
Copyright ©The Author(s) 2016.
World J Nephrol. Sep 6, 2016; 5(5): 471-481
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.471
Table 1 Baseline patient characteristics (n = 470), as a function of vitamin D status
All25(OH)D < 20 ng/mL25(OH)D 20-29 ng/mL25(OH)D ≥ 30 ng/mLP
n470252 (53%)154 (33%)64 (14%)
Age (yr)66.1 ± 12.965.8 ± 13.165.9 ± 11.968.1 ± 12.10.421
Male sex (%)309 (66%)162 (64%)101 (66%)46 (72%)0.303
High blood pressure (%)444 (95%)242 (96%)144 (94%)58 (91%)0.072
Dyslipidemia (%)311 (66%)168 (68%)101 (66%)42 (66%)0.646
Diabetes mellitus (%)183 (39%)114 (45%)53 (34%)16 (25%)0.001
Ischemic heart disease (%)104 (22%)60 (24%)33 (22%)11 (17%)0.224
Chronic heart failure (%)43 (9%)33 (13%)7 (5%)3 (5%)0.005
Stroke (%)52 (11%)30 (12%)15 (10%)7 (11%)0.668
Peripheral arterial disease (%)93 (20%)59 (24%)22 (14%)12 (19%)0.117
Stage of CKD (%)
3 (eGFR = 30-59 mL/min per 1.73 m2)221 (47%)103 (41%)84 (54%)34 (53%)0.002
4 (eGFR = 15-29 mL/min per 1.73 m2)205 (44%)105 (46%)64 (42%)26 (41%)
5 (eGFR < 15 mL/min per 1.73 m2)44 (9%)34 (13%)6 (4%)4 (6%)
Etiology of CKD (%)
Hypertension108 (23%)54 (21%)40 (26%)14 (22%)0.039
Diabetes mellitus108 (23%)72 (29%)29 (19%)7 (11%)
Tubulointerstitial disease65 (14%)24 (10%)25 (16%)16 (25%)
Glomerulonephritis47 (10%)26 (10%)15 (10%)6 (10%)
Unknown/others142 (30%)75 (30%)44 (29%)20 (32%)
Smoking (%)1
Never231 (53%)124 (52%)82 (58%)25 (44%)0.494
Ex-smoker144 (33%)81 (34%)44 (31%)19 (33%)
Active64 (14%)35 (14%)16 (11%)13 (23%)
Blood pressure (kPa)
Systolic19.0 ± 2.919.3 ± 2.918.6 ± 2.819.0 ± 3.10.085
Diastolic10.2 ± 1.510.2 ± 1.610.1 ± 1.410.3 ± 1.70.617
Pulse pressure (kPa)8.8 ± 2.59.1 ± 2.58.5 ± 2.58.7 ± 2.50.098
Body mass index (kg/m2)28.6 ± 5.128.8 ± 5.528.6 ± 4.627.7 ± 4.40.294
Underweight ( ≤ 18.5)6 (1%)4 (2%)1 (1%)1 (2%)0.353
Normal (18.6-24.9)96 (20%)50 (20%)30 (19%)16 (25%)
Overweight (25.0-29.9)210 (45%)111 (44%)68 (44%)31 (48%)
Obesity (> 29.9)158 (34%)87 (34%)55 (36%)16 (25%)
Waist (cm)
Males102.2 ± 12.0102.1 ± 13.0102.2 ± 10.6102.4 ± 11.50.989
Females97.8 ± 13.598.3 ± 14.797.7 ± 12.295.7 ± 11.40.760
ABPI1.01 ± 0.210.98 ± 0.201.04 ± 0.211.05 ± 0.220.013
Abnormal ABPI2194 (41%)100 (41%)66 (44%)28 (44%)0.539
Abnormal Kauppila score3107 (29%)52 (27%)35 (29%)20 (36%)0.183
Abnormal Adragao score4121 (32%)66 (33%)38 (30%)17 (29%)0.474
Vitamin D supplementation (%)43 (9%)16 (6%)17 (11%)10 (16%)0.012
Use of phosphate binders (%)72 (15%)47 (19%)16 (11%)9 (14%)0.105
Use of ACEI/ARB (%)365 (78%)196 (79%)121 (82%)48 (76%)0.947
Use of diuretic (%)287 (61%)173 (70%)88 (58%)26 (42%)< 0.001
Use of ESA (%)124 (26%)77 (31%)31 (20%)16 (25%)0.015
Table 2 Baseline laboratory values, as a function of vitamin D status
All (n = 470)25(OH)D < 20 ng/mL (n = 252)25(OH)D 20-29 ng/mL (n = 154)25(OH)D ≥ 30 ng/mL (n = 64)P
25-hydroxivitamin D (nmol/L)52 ± 2136 ± 961 ± 790 ± 16< 0.001
1,25(OH)2 vitamin D (pmol/L)103 ± 2897 ± 27111 ± 28107 ± 23< 0.001
Caalb (mmol/L)2.40 ± 0.202.40 ± 0.152.42 ± 0.232.45 ± 0.230.163
P (mmol/L)1.10 ± 0.261.10 ± 0.261.10 ± 0.261.07 ± 0.260.517
iPTH (ng/L)191 (85-97)106 (96-116)81 (73-91)64 (55-74)< 0.001
Creatinine (μmol/L)221 ± 97239 ± 106212 ± 88212 ± 880.017
eGFR (MDRD, mL/min per 1.73 m2)29.4 ± 11.528.1 ± 11.930.8 ± 10.830.5 ± 11.10.049
Urine protein excretion (g/24 h)120.592 (0.502-0.697)0.699 (0.573-0.853)0.448 (0.321-0.626)0.448 (0.271-0.742)0.034
hsCRP (nmol/L)136.2 (29.5-39.1)37.1 (33.3-41.0)36.2 (31.4-41.0)32.4 (26.7-39.1)0.506
Albumin (g/L)40 ± 539 ± 541 ± 540 ± 50.011
Total proteins (g/L)77 ± 1277 ± 1177 ± 1376 ± 140.877
Total cholesterol (mmol/L)4.7 ± 1.14.7 ± 1.14.7 ± 1.04.8 ± 1.10.603
HDL cholesterol (mmol/L)1.3 ± 0.41.3 ± 0.31.3 ± 0.41.3 ± 0.40.973
LDL cholesterol (mmol/L)2.7 ± 0.92.7 ± 0.92.7 ± 0.92.9 ± 0.80.344
Hemoglobin (g/L)130 ± 16129 ± 16132 ± 16132 ± 180.058
Ferritin (pmol/L)1225 (207-245)227 (202-252)216 (187-252)247 (191-319)0.635
Transferrin (μmol/L)3.0 ± 1.22.9 ± 1.23.0 ± 1.23.1 ± 1.30.289
Glucose (mmol/L)6.3 ± 2.26.3 ± 2.36.4 ± 2.45.9 ± 1.50.241
Table 3 Adjusted Cox proportional hazards models of patient survival (events = 46)
ModelCovariates controlled forAdjusted HR (95%CI)P
0 (Unadjusted)25-hydroxivitamin D levels (mg/dL)0.95 (0.91-0.99)0.009
125-hydroxivitamin D levels (mg/dL) + age0.95 (0.91-0.99)0.009
2Model 1 + diabetes mellitus, ischemic heart disease, chronic heart failure0.96 (0.92-0.99)0.028
3Model 1 + peripheral arterial disease, abnormal ABPI1, phosphorous (mg/dL)0.95 (0.92-0.99)0.023
4Model 1 + DBP (mm Hg), 1,25(OH)2 vitamin D (pg/mL), estimated GFR (mL/min per 1.73 m2)0.96 (0.92-0.99)0.020
5Model 1 + vascular calcification [Kauppila score (log), Adragao score (log)], CKD stage 50.95 (0.91-1.00)0.050
6Model 1 + obesity, hemoglobin (g/L), albumin (g/dL)0.95 (0.92-0.99)0.019
Table 4 Multivariate Cox regression analysis in relation to renal end point (events = 156)
HR (95%CI)P value
25-hydroxivitamin D (ng/mL)0.97 (0.95-0.99)0.004
Age (yr)0.99 (0.97-1.00)0.044
Male sex2.20 (1.47-3.30)< 0.001
Estimated GFR (mL/min per 1.73 m2)0.93 (0.91-0.95)< 0.001
ABPI (mmHg)0.23 (0.10-0.53)0.001
Hemoglobin (g/L)0.84 (0.78-0.94)0.001

  • Citation: Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol 2016; 5(5): 471-481
  • URL: https://www.wjgnet.com/2220-6124/full/v5/i5/471.htm
  • DOI: https://dx.doi.org/10.5527/wjn.v5.i5.471